Register for our free email digests:
Division of Bayer AG
Latest From Aura Biosciences Inc.
Moderna and Intarcia lead recent fundraisings; big pharma backing includes Novartis leading Series A for Inflazome and Pfizer for diabetes play Antolrx. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August through September 2016.
Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.
$10 million Series B will enable lead candidate AX-024 to advance into Phase IIa in undetermined autoimmune indications.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2015.
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Bayer AG
- Senior Management
Andrew Kay, Pres. & CEO
Roger Harrison, PhD, CBO
Andreas Menrad, PhD, CSO
- Contact Info
Phone: (47) 23 00 79 90
Kjelsasveien 172 A
P.O. Box 54 Oslo, NO-0411
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.